Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Top Cited Papers
- 1 February 2004
- journal article
- genitourinary cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (3), 454-463
- https://doi.org/10.1200/jco.2004.06.132
Abstract
Purpose To describe survival in previously treated patients with metastatic renal cell carcinoma (RCC) who are candidates for clinical trials of new agents as second-line therapy. Patients and Methods The relationship between pretreatment clinical features and survival was studied in 251 patients with advanced RCC treated during 29 consecutive clinical trials between 1975 and 2002. Clinical features were first examined in univariate analyses, and then a stepwise modeling approach based on Cox regression was used to form a multivariate model. Results Median survival for the 251 patients was 10.2 months and differed according to year of treatment, with patients treated after 1990 showing longer survival. In this group, the median overall survival time was 12.7 months. Because the purpose of this analysis was to establish prognostic factors for present-day clinical trial design, prognostic factor analysis was performed on these patients. Pretreatment features associated with a shorter survival in the multiva...Keywords
This publication has 41 references indexed in Scilit:
- Erratum for Volume 21, pg. 3972Journal of Clinical Oncology, 2004
- A standardization method to adjust for the effect of patient selection in phase II clinical trialsStatistics in Medicine, 2001
- Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell TransplantationNew England Journal of Medicine, 2000
- SYSTEMIC THERAPY FOR RENAL CELL CARCINOMAJournal of Urology, 2000
- A bootstrap resampling procedure for model building: Application to the cox regression modelStatistics in Medicine, 1992
- Phase II trial of Didemnin B in patients with advanced renal cell carcinomaInvestigational New Drugs, 1990
- Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephromaCancer Chemotherapy and Pharmacology, 1985
- Phase II trial of 4ʼepi-adriamycin for advanced hypernephromaAmerican Journal of Clinical Oncology, 1983
- Albumin as an aid to the interpretation of serum calciumClinica Chimica Acta; International Journal of Clinical Chemistry, 1971
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958